Abstract: Objective : To study the result of two -way combinated chemotheraphy for epithelialovary carcinoma of stage Ⅲ. Methods : A total of 92 cases with epithelial ovary carcinoma at stage Ⅲwere randomized into two groups. The patients received two-way chemotheraphy in group A (46 cases)and received routine intravenous chemotheraphy in group B (44 cases). Results : The 1- and N -year survial rate of the two groups was 90.9% vs 83.3% (P >0.05) and 80.0% Vs 40.0% (P<0.05),respectively; the 1- and 3-year disease-frdee survial rate of the two groups was 81.8% vs 50.0% (P<0.05) and 60.0% vs 20.0% (P<0.05), respectively. Conclusion : These results demonstrate that the two-way chemotheraphy is obviously better than the adjuvant chemotheraphy for the patients with stage Ⅲ epithelial ovary carcinoma.